Regulus Therapeutics Inc. RGLS
We take great care to ensure that the data presented and summarized in this overview for Regulus Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGLS
View all-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$16.2 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$8.15 Million0.73% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$6.3 Million1.54% of portfolio
-
Octagon Capital Advisors LP New York, NY4.85MShares$6.11 Million1.71% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.97MShares$5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.26MShares$4.11 Million0.23% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$2.76 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2MShares$2.52 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.28MShares$1.61 Million0.0% of portfolio
Latest Institutional Activity in RGLS
Top Purchases
Top Sells
About RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Transactions at RGLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2025
|
David Baltimore |
BUY
Open market or private purchase
|
Direct |
19,610
+46.94%
|
$19,610
$1.06 P/Share
|
|
Jan 30
2025
|
Joseph P Hagan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+16.09%
|
$50,000
$1.09 P/Share
|
|
Jan 14
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,088
-10.06%
|
$5,088
$1.26 P/Share
|
|
Jan 14
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,764
-5.29%
|
$11,764
$1.26 P/Share
|
|
Jan 14
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,088
-9.31%
|
$5,088
$1.26 P/Share
|
|
Jan 13
2025
|
Preston Klassen President & Head of R & D |
SELL
Open market or private sale
|
Direct |
31,445
-46.59%
|
$31,445
$1.26 P/Share
|
|
Jan 13
2025
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
38,716
-43.36%
|
$38,716
$1.26 P/Share
|
|
Jan 13
2025
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
115,290
-34.12%
|
$115,290
$1.26 P/Share
|
|
Jan 13
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
38,547
-41.37%
|
$38,547
$1.26 P/Share
|
|
Jan 09
2025
|
Preston Klassen President & Head of R & D |
BUY
Grant, award, or other acquisition
|
Direct |
67,500
+40.38%
|
$67,500
$1.33 P/Share
|
|
Jan 09
2025
|
Christopher Ray Aker Sr. VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
84,125
+31.31%
|
$84,125
$1.33 P/Share
|
|
Jan 09
2025
|
Crispina Calsada Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,500
+33.42%
|
$83,500
$1.33 P/Share
|
|
Jan 09
2025
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
280,750
+29.87%
|
$280,750
$1.33 P/Share
|
|
Jul 25
2024
|
Kathryn J Collier |
BUY
Open market or private purchase
|
Direct |
4,000
+37.24%
|
$4,000
$1.82 P/Share
|
|
Mar 14
2024
|
Stelios Papadopoulos |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+20.35%
|
$250,000
$1.6 P/Share
|
|
Jan 18
2024
|
Joseph P Hagan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,580
-20.34%
|
$14,580
$1.19 P/Share
|
|
Jan 18
2024
|
Christopher Ray Aker Sr. VP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,468
-35.22%
|
$5,468
$1.19 P/Share
|
|
Jan 18
2024
|
Crispina Calsada Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,468
-48.6%
|
$5,468
$1.19 P/Share
|
|
Jan 12
2024
|
Joseph P Hagan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+29.5%
|
-
|
|
Jan 12
2024
|
Christopher Ray Aker Sr. VP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+42.02%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 73.6K shares |
|---|---|
| Grant, award, or other acquisition | 766K shares |
| Open market or private sale | 246K shares |
|---|